Fabrics containing camouflage patterns are produced from dyes wherein at least certain of the colors contained in the pattern contain a low reflectance dye. The low reflectance dye is added to one or more colors in the pattern in order to preserve the camouflage pattern when viewed through night vision goggles as relatively long wavelengths, such at wavelengths greater than 900 nm. In one embodiment, the low reflectance dye comprises a thiazine. The low reflectance dye is blended with other dyes to produce colors in the pattern. By altering the concentration of the low reflectance dye in each of the colors, the colors contained in the camouflage pattern remain separate and distinct even at relatively long wavelengths.

A compound comprises at least one fluorescent moiety covalently bound to at least one second moiety selected from the group consisting of leuco moieties and chromophore moieties.

The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.

The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.

An organic electroluminescence device includes an anode, a cathode and an emitting layer, in which the emitting layer includes a first compound and a second compound and each of the first compound and the second compound is a compound emitting thermally activated delayed fluorescence.

An organic electroluminescence device includes an anode, a cathode and an emitting layer, in which the emitting layer includes a first compound and a second compound and each of the first compound and the second compound is a compound emitting thermally activated delayed fluorescence.

A colored composition of the present invention includes a dye compound having an anionic moiety including at least one of a structure represented by the following General Formula (A1), a structure represented by the following General Formula (A2), and a structure containing a boron atom, and a dye structure having a cationic moiety, in which the anionic moiety and the cationic moiety are bonded to each other via a covalent bond and present in the same molecule; a curable compound; and a solvent.

##STR00001## (in General Formula (A1), R.sup.1 and R.sup.2 each independently represent SO.sub.2 or CO)

##STR00002## (in General Formula (A2), R.sup.3 represents SO.sub.2 or CO; and R.sup.4 and R.sup.5 each independently represent SO.sub.2, CO, or CN)

A colored composition of the present invention includes a dye compound having an anionic moiety including at least one of a structure represented by the following General Formula (A1), a structure represented by the following General Formula (A2), and a structure containing a boron atom, and a dye structure having a cationic moiety, in which the anionic moiety and the cationic moiety are bonded to each other via a covalent bond and present in the same molecule; a curable compound; and a solvent.

##STR00001## (in General Formula (A1), R.sup.1 and R.sup.2 each independently represent SO.sub.2 or CO)

##STR00002## (in General Formula (A2), R.sup.3 represents SO.sub.2 or CO; and R.sup.4 and R.sup.5 each independently represent SO.sub.2, CO, or CN)

Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula:

##STR00001##

wherein: R.sup.1 and R.sup.9 are independently selected from: H; C.sub.1-4alkyl; C.sub.2-4 alkenyl; and halogenated C.sub.1-4 alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: H; C.sub.1-4 alkyl; C.sub.2-4 alkenyl; and halogenated C.sub.1-4 alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: H; C.sub.1-4 alkyl; C.sub.2-4 alkenyl; and halogenated C.sub.1-4 alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula:

##STR00001##

wherein: R.sup.1 and R.sup.9 are independently selected from: H; C.sub.1-4alkyl; C.sub.2-4 alkenyl; and halogenated C.sub.1-4 alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: H; C.sub.1-4 alkyl; C.sub.2-4 alkenyl; and halogenated C.sub.1-4 alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: H; C.sub.1-4 alkyl; C.sub.2-4 alkenyl; and halogenated C.sub.1-4 alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.